drugset
drugset / Trial / NCT04121078

A Study to Evaluate the Effect of Single-Dose Intravenous Rifampin as a Prototypic Inhibitor of Organic Anion Transporting Polypeptide (OATP) 1B1 and OATP1B3 on the Single-Dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult Participants

NCT04121078 ↗

Phase 1 Completed 12 enrolled Millennium Pharmaceuticals, Inc.
RandomizedCrossoverOpen-labelOther

Summary

The purpose of this study is to evaluate the effect of single dose intravenous rifampin on the single-dose PK of orally administered TAK-906.

Timeline

Start
2019-10-15
Primary completion
2019-11-04
Completion
2019-11-16

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Rifampin Small molecule 600 mg Intravenous
Subject Trazpiroben Small molecule 25 mg Oral

Indications

No indication recorded.